MétaCan
Menu
Back to cohort

Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG‐IFN α‐2a (40KD) (PEGASYS<sup>®</sup>)

2009· article· en· W2062408321 on OpenAlexaff
Brian Bressler, Ka Wang, Joseph F. Grippo, E. Jenny Heathcote

Bibliographic record

VenueBritish Journal of Clinical Pharmacology · 2009
Typearticle
Languageen
FieldMedicine
TopicHepatitis C virus research
Canadian institutionsUniversity of TorontoSt. Paul's HospitalUniversity Health NetworkUniversity of British Columbia
Fundersnot available
KeywordsMedicinePEG ratioInternal medicineGastroenterologyRibavirinPopulationPegylated interferonChronic hepatitisSurgeryImmunologyVirus

Abstract

fetched live from OpenAlex

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Obesity is a negative predictor of successful treatment in patients with chronic hepatitis C treated with peginterferon (PEG‐IFN) and ribavirin. • Obese patients may have suboptimal exposure of PEG‐IFN contributing to the poor responses seen in this patient population. • In non‐obese patients doses of PEG‐IFN α‐2a (40KD) up to 360 µg week−1 have shown dose proportional pharmacokinetics. WHAT THIS STUDY ADDS • Here we show that among obese patients treated with the standard dose of PEG‐IFN α‐2a (40KD) (180 µg week−1) drug exposure was lower than that found in a large set of unpublished data among non‐obese patients, but was generally similar to exposures found in a large set of unpublished data among similarly obese patients receiving the same dose of PEG‐IFN α‐2a (40KD). • By increasing the dose of PEG‐IFN α‐2a (40KD) from 180 µg week−1 to 270 µg week−1 one can increase PEG‐IFN α‐2a (40KD) exposure, thereby potentially compensating for the apparent reduction in drug exposure in obese patients. AIMS To evaluate whether higher doses of peginterferon α‐2a (40KD) [PEG‐IFN α‐2a (40KD)] can compensate for lower exposure observed among obese patients with chronic hepatitis C (CHC) treated with the standard dose of PEG‐IFN α‐2a (40KD). METHODS Noncirrhotic, obese (body mass index ≥30 kg m−2) patients with CHC participated in a single‐centre, open‐label study. Patients were randomized to 180 or 270 µg week−1 PEG‐IFN α‐2a (40KD) + ribavirin (1000/1200 mg day−1) for 48 weeks. Blood samples were collected predose and up to 168 h after the first dose and at week 12 for pharmacokinetic analysis. Trough serum concentrations (Ctrough) were determined up to week 24. RESULTS In the 180 µg week−1 group mean ± SD steady‐state (week 12) estimates of AUC0–168 (ng h−1 ml−1), Cmax (ng ml−1) and CL/F (l h−1) were 2154 ± 919, 13.8 ± 6.7 and 0.102 ± 0.051, respectively. In the 270 µg week−1 group, estimates were 3374 ± 1844, 23.4 ± 10.7 and 0.090 ± 0.042, respectively. The mean (range) Ctrough (ng ml−1) was 11.2 (4.4–18.5) in the 180 µg week−1 group and 16.1 (0.4–44.2) in the 270 µg week−1 group. Overall, 14 of 20 (70%) and 16 of 20 (80%) patients in the 180 µg week−1 and 270 µg week−1 groups were infected with hepatitis C virus genotype 1 or 4. In the 180 µg week−1 and 270 µg week−1 groups 14 of 20 (70%) and 15 of 19 (79%) patients, respectively, achieved a sustained viral response. Safety was similar between groups. CONCLUSIONS Mean PEG‐IFN α‐2a (40KD) exposure was dose proportional from 180 to 270 µg week−1. Increasing PEG‐IFN α‐2a (40KD) from 180 to 270 µg week−1 achieves higher serum drug exposure in obese patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.387
Teacher spread0.355 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations15
Published2009
Admission routes1
Has abstractyes

Explore more

Same venueBritish Journal of Clinical PharmacologySame topicHepatitis C virus researchFrench-language works237,207